In the latest trading session, ABIVAX SA, a prominent biotechnology company based in France, experienced a modest gain in its share price, reflecting the broader upward movement in the European equity market. This positive trend was particularly evident in the health sector, where stocks led the Stoxx 600 index, buoyed by several European companies reporting stronger-than-expected earnings. ABIVAX’s share price rose in line with its peers, underscoring the market’s favorable view of the company’s recent performance and outlook.
ABIVAX SA, incorporated in 2013 and headquartered in Paris, specializes in developing, marketing, and commercializing anti-viral therapies and therapeutic vaccines for the treatment of infectious diseases, primarily in Asia and Latin America. The company’s innovative pipeline includes several promising candidates at various stages of clinical development. Notably, ABX 464 is in Phase II clinical trials, aiming to provide a sustained viral remission or functional cure for patients with HIV/AIDS. Additionally, ABX 203, a therapeutic vaccine candidate, is in Phase IIb/III trials for the treatment of chronic hepatitis B, while ABX 196, an art immune enhancer candidate, has completed Phase I clinical trials for iNKT cells.
Beyond these, ABIVAX SA is also developing vaccines for typhoid, meningitis B and C, and leptospirosis. The company’s pre-clinical programs include ABX 220 for the treatment of Dengue fever, ABX 544, a drug candidate for the treatment of Ebola based on polyclonal antibodies, and ABX 311 for the treatment of Chikungunya. These initiatives highlight ABIVAX’s commitment to addressing a wide range of infectious diseases through innovative therapeutic solutions.
The company’s strategic collaborations further bolster its research and development efforts. ABIVAX SA has license contracts with the French National Centre for Scientific Research, the University of Montpellier 2 Science and Technology, and the Curie Institute. Additionally, it has formed a partnership with the Cuban Centro de Ingenia Genetica y de Biotecnologia, enhancing its global reach and research capabilities.
With a market capitalization of 9.84 billion EUR and a close price of 114.1 EUR as of August 6, 2026, ABIVAX SA’s financial metrics reflect its significant presence in the biotechnology sector. Despite a negative price-earnings ratio of -25.13, the company’s recent share price performance and strategic initiatives suggest a positive trajectory. As the broader European equity market continues to exhibit solid earnings reports, ABIVAX SA’s alignment with these trends positions it favorably for future growth and development in the competitive biopharmaceutical landscape.
